Riboscience
Harshdeep (Hersh) Kaur currently serves as the Director of Clinical Operations at Riboscience since June 2024. Previously, Kaur held the position of Associate Director of Clinical Operations at NGM Biopharmaceuticals from August 2022 to June 2024 and has extensive experience at Gilead Sciences, where Kaur advanced through various roles in Clinical Operations from August 2014 to August 2022, including Sr. Clinical Trials Manager. Kaur's earlier career includes positions as a Clinical Research Coordinator at Stanford University and Research Associate roles at Amgen and Five Prime Therapeutics. Kaur holds a Clinical Research Conduct and Management Certificate from the University of California, Berkeley Extension, a Master's Degree in Pathology and Biochemistry from the University of Southern California, and an MBBS from Government Medical College and Hospital in Aurangabad, India.
This person is not in any teams
Riboscience
Riboscience is a clinical stage biotechnology company developing treatments for serious infectious diseases and cancer. We apply ribose and structure-guided design technologies to the discovery of drugs that target proteins that are essential and unique to specific infectious pathogens, tumor cells or the anti-tumor immune response.